Literature DB >> 10809147

Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine.

S A White1, A F LoBuglio, R B Arani, M J Pike, S E Moore, D L Barlow, R M Conry.   

Abstract

BACKGROUND: We have previously reported that intramuscular, intradermal or epidermal gene gun administration of a plasmid encoding carcinoembryonic antigen (CEA) under transcriptional regulatory control of the cytomegalovirus (CMV) early promoter/enhancer elicits CEA-specific humoral and cellular immune responses in mice with resultant immunoprotection against challenge with syngeneic, CEA-expressing colon adenocarcinoma cells.
METHODS: In the present work, we examine the ability of this DNA vaccine construct (pCEA) to elicit CEA-specific immunity following intrasplenic administration. Groups of mice were immunized with pCEA by intrasplenic or intramuscular injection. Six weeks later, mice were evaluated for the presence of anti-CEA humoral responses and were challenged with syngeneic, CEA-expressing colon carcinoma cells.
RESULTS: Intrasplenic administration of pCEA produced a frequency of CEA-specific antibody responses comparable to that elicited by intramuscular pCEA inoculation. Both intrasplenic and intramuscular administration of pCEA generated IgG2a antibody responses to CEA, consistent with the induction of T helper-1-biased immune responses. In addition, partial immunoprotection against tumor challenge was observed after a single plasmid DNA dose by either route of administration. Subsequent studies revealed that antibody responses to intrasplenic DNA vaccination are dose and schedule dependent.
CONCLUSION: These findings support future investigations of DNA vaccination strategies that specifically promote the uptake of plasmid by splenocytes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10809147     DOI: 10.1002/(SICI)1521-2254(200003/04)2:2<135::AID-JGM88>3.0.CO;2-O

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  3 in total

1.  Intraoperative subcutaneous or intrasplenic vaccination with modified autologous tumor cells leads to enhanced survival in a mouse tumor model.

Authors:  Arne Dietrich; Christoph Stockmar; Gabriela Aust; Susan Endesfelder; Anke Guetz; Ulrich Sack; Manfred Schoenfelder; Johann Hauss
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-04       Impact factor: 4.553

Review 2.  p53 gene in treatment of hepatic carcinoma: status quo.

Authors:  Yong-Song Guan; Zi La; Lin Yang; Qing He; Ping Li
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

3.  The impact of intraoperative vaccination with IL-12 modified autologous tumor cells in the Lewis lung carcinoma mouse model.

Authors:  Arne Dietrich; Christoph Stockmar; Susan Endesfelder; Anke Guetz; Gabriela Aust
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-10       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.